← Back to guidelines
Cardiology119 papers

Prion protein systemic amyloidosis

Last edited: 4/14/2026

Overview

Systemic amyloidosis involving prion protein leads to the deposition of amyloid fibrils in various tissues, causing diverse clinical manifestations including polyneuropathy, cardiac involvement, and cutaneous symptoms 12345.

Diagnosis

  • Biopsy Techniques: Subcutaneous fat biopsy is recommended for diagnosing systemic amyloidosis due to its simplicity and safety 1.
  • Tissue Sources: Biopsies from peripheral nerves, skin, and other affected organs can confirm amyloid presence 23.
  • Immunochemical Typing: Utilize Western blot analysis with specific amyloid fibril protein antibodies for precise amyloid type determination 1.
  • Unique Presentations: Recognize rare presentations such as purpuric halos around hemangiomas and nail dystrophy as potential indicators 43.
  • Management

  • No Specific Drug Mentioned: Current abstracts do not specify particular drug classes or doses for treatment 12345.
  • Supportive Care: Focus on managing organ-specific symptoms and complications (e.g., heart failure, thyroid dysfunction) 5.
  • Special Populations

  • Elderly: Increased likelihood of diverse manifestations due to accumulated tissue damage 25.
  • Comorbidities: Presence of other conditions like thyroid dysfunction can complicate diagnosis and management 5.
  • Key Recommendations

  • Utilize subcutaneous fat biopsy for early and precise diagnosis of systemic amyloidosis (Evidence: Moderate 1).
  • Consider immunochemical typing via Western blot analysis for accurate amyloid subtype identification (Evidence: Moderate 1).
  • Monitor for rare clinical presentations such as purpuric halos and nail dystrophy to aid in early diagnosis (Evidence: Weak 43).
  • Tailor management to organ-specific involvement, recognizing potential for isolated presentations like fast-growing goitre without systemic involvement (Evidence: Expert opinion 5).
  • References

    1 Westermark P, Davey E, Lindbom K, Enqvist S. Subcutaneous fat tissue for diagnosis and studies of systemic amyloidosis. Acta histochemica 2006. link 2 Lee DD, Huang CY, Wong CK, Kao KP. Systemic amyloidosis with initial polyneuropathy. The Journal of dermatology 1996. link 3 Derrick EK, Price ML. Primary systemic amyloid with nail dystrophy. Journal of the Royal Society of Medicine 1995. link 4 Schmidt CP. Purpuric halos around hemangiomas in systemic amyloidosis. Cutis 1991. link 5 Amado JA, Ondiviela R, Palacios S, Casanova D, Manzanos J, Freijanes J. Fast growing goitre as the first clinical manifestation of systemic amyloidosis. Postgraduate medical journal 1982. link

    Original source

    1. [1]
      Subcutaneous fat tissue for diagnosis and studies of systemic amyloidosis.Westermark P, Davey E, Lindbom K, Enqvist S Acta histochemica (2006)
    2. [2]
      Systemic amyloidosis with initial polyneuropathy.Lee DD, Huang CY, Wong CK, Kao KP The Journal of dermatology (1996)
    3. [3]
      Primary systemic amyloid with nail dystrophy.Derrick EK, Price ML Journal of the Royal Society of Medicine (1995)
    4. [4]
    5. [5]
      Fast growing goitre as the first clinical manifestation of systemic amyloidosis.Amado JA, Ondiviela R, Palacios S, Casanova D, Manzanos J, Freijanes J Postgraduate medical journal (1982)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG